A5080981511- Glioma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Radiomics and Machine Learning in Medical Imaging
- Brain Metastases and Treatment
- Calcium signaling and nucleotide metabolism
- Multiple Myeloma Research and Treatments
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Cancer Genomics and Diagnostics
- Cancer therapeutics and mechanisms
- Cancer Immunotherapy and Biomarkers
- Cancer Research and Treatments
- Toxin Mechanisms and Immunotoxins
- Lymphoma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Meningioma and schwannoma management
- Epigenetics and DNA Methylation
- Ethics in Clinical Research
- Immunotherapy and Immune Responses
- Chromatin Remodeling and Cancer
- Chronic Myeloid Leukemia Treatments
- Acute Lymphoblastic Leukemia research
- Esophageal Cancer Research and Treatment
- Multiple and Secondary Primary Cancers
- Circular RNAs in diseases
West Virginia University
2020-2025
Virginia Cancer Institute
2020-2021
Mayo Clinic in Florida
2017-2021
WinnMed
2018-2019
Jacksonville College
2018
Abstract With improving survivorship in chronic lymphocytic leukemia (CLL), the risk of second primary malignancies (SPMs) has not been systematically addressed. Differences for SPMs among CLL survivors from Surveillance, Epidemiology, and End Results (SEER) database (1973–2015) were compared to individual expected general population. In ~270,000 person-year follow-up, 6487 new diagnosed with a standardized incidence ratio (SIR) 1.2 (95% CI:1.17–1.23). The higher was both solid (SIR 1.15;...
CD38 has emerged as a high-impact therapeutic target in multiple myeloma, with the approval of daratumumab (anti-CD38 mAb). The clinical importance patients chronic lymphocytic leukemia (CLL) been known for over 2 decades, although it's relevance CLL remains understudied.We investigated biological effects and antitumor mechanisms engaged by primary cells. Besides its immune-effector (antibody-dependent cell-mediated cytotoxicity, complement-dependent death, antibody-dependent cellular...
Abstract Patients with chronic lymphocytic leukemia (CLL) are characterized by monoclonal expansion of CD5+CD23+CD27+CD19+κ/λ+ B lymphocytes and clinically noted to have profound immune suppression. In these patients, it has been recently shown that a subset cells possesses regulatory functions secretes high levels interleukin 10 (IL-10). Our investigation identified CLL CD19+CD24+CD38hi immunophenotype (B cell [Breg]–like cells) produce amounts IL-10 transforming growth factor β (TGF-β)...
Introduction: Glioblastoma (GBM) is a fatal malignancy of the brain. It has been observed that patients in rural areas with GBM have worse overall survival. Higher morbidity and mortality these attributed to lack optimal access clinical care participation trials. However, projected number cases risk related do not reflect reality Appalachian region. In this retrospective study, we reviewed survival data Appalachia. Methods: 169 ( 761) grade 4 IDH WT from 1/16/2019 through 7/1/2024 were...
Abstract Gliomas are the most prevalent neurological cancer in USA and care modalities not able to effectively combat these aggressive malignancies. Identifying new, more effective treatments require a deep understanding of complex genetic variations relevant pathway associations behind cancers. Drawing connections between gene mutations with responsive target can help drive therapy selections enhance patient survival. We have performed extensive molecular profiling Capicua ( CIC) , tumor...
The blood-brain barrier is the selectively permeable vasculature of brain vital for maintaining homeostasis and neurological function. Low permeability beneficial in presence toxins pathogens blood. However, metastatic tumors, it a challenge drug delivery. Although blood-tumor slightly leaky, still not permissive enough to allow accumulation therapeutic concentrations metastases. Herein, we discuss differences between primary tumors vasculature, effects therapeutics on barrier,...
Standard-of-care first-line therapy for patients with newly diagnosed glioblastoma (ndGBM) is maximal safe surgical resection, then concurrent radiotherapy and temozolomide, followed by maintenance temozolomide. IGV-001, the first product of Goldspire™ platform, a first-in-class autologous immunotherapeutic that combines personalized whole tumor–derived cells an antisense oligonucleotide (IMV-001) in implantable biodiffusion chambers, intent to induce tumor-specific immune response ndGBM....
Summary CD38 is expressed on Waldenström macroglobulinaemia (WM) cells, but its role as a therapeutic target remains undefined. With recent approval of the anti‐CD38 monoclonal antibody, daratumumab (Dara), we hypothesized that blocking would be lethal to WM cells. In vitro Dara treatment cells (including ibrutinib‐resistant lines) elicited antibody‐dependent cellular cytotoxicity (ADCC), complement‐dependent (CDC), cell phagocytosis (ADCP) and direct apoptosis. vivo , was well tolerated...
Concern exists that the clinical trial populations differ from respective cancer in terms of their age distribution affecting generalizability results, especially underrepresented minorities. We hypothesized trials do not report race are likely to suffer a higher degree disparity.Food and Drug Administration (FDA) drug approvals July 2007 June 2019 were reviewed identify oncology approvals, with details selected. The outcomes studied weighted mean difference between population real-world for...
Background: Relapsed medulloblastoma (MB) poses a significant therapeutic challenge due to its highly immunosuppressive tumor microenvironment. Immune checkpoint inhibitors (ICIs) have struggled mitigate this challenge, largely low T-cell infiltration and minimal PD-L1 expression. Identifying the mechanisms driving is crucial for developing more effective immunotherapies. Methods: We utilize syngeneic mouse model investigate immune microenvironment of MB compare our findings transcriptomic...
e14030 Background: Glioblastoma (GBM) is the primary malignant tumor of brain with a dismal outcome. Current management includes maximal safe surgical resection, radiation therapy concomitant and adjuvant temozolomide (TMZ). Its recurrence inevitable limited available therapies. In era targeted therapeutics, CD38 can be potential target especially availability Daratumumab; an FDA approved Anti-CD38 monoclonal antibody. expressed on 25% tumor-microglia macrophages that form 40% bulk glioma....
Abstract Glioblastoma (GBM) is an aggressive primary malignant brain tumor with poor prognosis. Surgical resection followed by chemoradiotherapy (temozolomide [TMZ] + radiation) results in a median survival of only 12-15 months. Recently, immunotherapy targeted antibodies, therapeutic vaccination and adoptive cell therapy offers promising option for treating GBM. Herein we observed that CD38, catalytic receptor regulator NAD homeostasis, expressed on GBM cells their microenvironment...
2026 Background: Bevacizumab remains the standard second line therapy in glioblastoma (GBM) with reported improved progression free survival, but not overall survival. We investigated a large clinico-genomic database of GBM patients treated bevacizumab for molecular alterations associated treatment outcome. Methods: Molecular profiles were tested by next-generation sequencing (NGS) DNA (592 genes, NextSeq or whole-exome sequencing, Novaseq) and RNA (whole transcriptome NovaSeq) at Caris Life...
2082 Background: Recent insights into the molecular basis of diffuse hemispheric glioma, H3 G34-mutant (DHG-G34), an incurable high-grade have opened new therapeutic possibilities. The oncohistone mutation in DHG-G34 impairs epigenetic regulator SETD2, which normally orchestrates DNA-mismatch-repair and negatively regulates transcriptional silencing activity Polycomb Repressive Complex 2 (PRC2). In DHG-G34, a mismatch-repair-deficiency phenotype is predicted, but anti-tumor immune response...
8646 Background: Brain metastasis (BM) in NSCLCs have a unique tumor micro-environment (TME) characterized by distinct immune-constituents and the presence of blood-brain barrier, differentiating them from primary NSCLC tumors (PT). Despite high incidence BM, earlier trials indicated that less than 15% BM patients benefit immune checkpoint inhibitors (ICIs). We TME to potentially identify subset who may respond favorably ICIs. Methods: 36,726 samples were analyzed NGS DNA (592-gene) RNA...
e14034 Background: In cancers of the nervous system such as neuroblastoma (NB), ubiquitin ligase UBE4B directly ubiquitinates growth factor receptors (GFRs), influencing their trafficking and lysosomal degradation. While diverse functions are acknowledged, we hypothesize that expression has distinct associations with outcomes in pediatric versus adult cancers. We examined impact on glioblastoma (GBM) development, growth, metastasis by correlating its patient across age groups. Methods:...